Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: Laryngoscope. 2011 May;121(5):978–982. doi: 10.1002/lary.21724

Figure 1.

Figure 1

Figure 1

A, Tumor growth curve in the minimal residual disease model comparing sirolimus to control, revealing a significant difference in tumor growth inhibition in the sirolimus treated group. B, Tumor growth curve: volume growth rates (mm3 per mouse per day) increased on “no treatment” days, resulting in growth “spikes” in the sirolimus treatment group.